CN Patent

CN120957707A — 可复溶干粉配制品及其使用方法

Assigned to Sanofi Pasteur Inc · Expires 2025-11-14 · 1y expired

What this patent protects

本披露涉及复溶的mRNA干粉颗粒用于肠胃外施用的用途。本披露还涉及一种生成干粉颗粒的方法，该干粉颗粒添加了适宜赋形剂，以实现最佳的热稳定性和体内表达。

USPTO Abstract

本披露涉及复溶的mRNA干粉颗粒用于肠胃外施用的用途。本披露还涉及一种生成干粉颗粒的方法，该干粉颗粒添加了适宜赋形剂，以实现最佳的热稳定性和体内表达。

Drugs covered by this patent

Onpattro (PATISIRAN SODIUM) · Alnylam Pharmaceuticals

Patent Metadata

Patent number: CN120957707A
Jurisdiction: CN
Classification: —
Expires: 2025-11-14
Drug substance claim: No
Drug product claim: No
Assignee: Sanofi Pasteur Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.